Valentin Dérangère

Author

Valentin Dérangère

Also Known As

Derangere, Valentin, Derangère, Valentin, V Derangère, V. Derangere, V. Derangère, Valentin Derangere, Valentin Derangère, Valentin Dérangère

218

Publications

Citations

H-Index

Concepts

All Affiliations

Centre Georges François Leclerc Inserm Université de Bourgogne Genomic and Immunotherapy Medical Institute Centre de recherche Translationnelle en Médecine moléculaire

About

Valentin Dérangère is an author at Centre Georges François Leclerc specializing in medicine, immunology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	20	3K
2	Immunology	15	15	2.8K
3	Cell Biology	11	11	2.4K
4	Health Sciences	2	2	89
5	Gastroenterology	1	1	15

Valentin Dérangère

Publications

5.6K

Citations

H-Index

Page 1

	Year	Citations
Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth Mélanie Bruchard, Grégoire Mignot, Valentin Dérangère, Nature Medicine InflammationTumor BiologyCancer ImmunosurveillanceMedicineNlrp3 Inflammasome	2012	763
The receptor NLRP3 is a transcriptional regulator of TH2 differentiation Mélanie Bruchard, Cédric Rébé, Valentin Dérangère, Nature Immunology Transcriptional RegulationSignal TransductionSignaling PathwayImmunologyReceptor (Biochemistry)	2015	396
Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports colorectal cancer chemoresistance Alexia K. Cotte, Virginie Aires, Maxime Fredon, Nature Communications	2018	338
Stat3 and Gfi-1 Transcription Factors Control Th17 Cell Immunosuppressive Activity via the Regulation of Ectonucleotidase Expression Fanny Chalmin, Grégoire Mignot, Mélanie Bruchard, Immunity InflammationEctonucleotidase ExpressionTranscriptional RegulationCytokineSignal Transduction	2012	322
Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen Emeric Limagne, Romain Euvrard, Marion Thibaudin, Cancer Research	2016	256
Tracking the evolution of circulating exosomal‐PD‐L1 to monitor melanoma patients Marine Cordonnier, Charlée Nardin, Gaëtan Chanteloup, Journal of Extracellular Vesicles ImmunologyImmunoeditingPathologyExtracellular MicrovesiclesImmunotherapeutics	2020	251
Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients Audrey Hennequin, Valentin Dérangère, Romain Boidot, OncoImmunology	2015	219
The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells Frédérique Végran, Hélène Berger, Romain Boidot, Nature Immunology CytokineTh9 CellsT-regulatory CellIl-21-dependent Anticancer FunctionsImmunology	2014	212
Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination M. Grapin, Corentin Richard, Emeric Limagne, Journal for ImmunoTherapy of Cancer	2019	205
MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells Emeric Limagne, Lisa Nuttin, Marion Thibaudin, Cancer Cell Cancer ImmunosurveillanceOncologyMedicineImmunologyImmune Checkpoint Inhibitor	2022	199

Page 1